PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED
平安健康醫療科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1833)

ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

The board of directors (the "**Board**") of Ping An Healthcare and Technology Company Limited (the "**Company**") is pleased to announce that the unaudited interim results of the Company and its subsidiaries (the "**Group**") for the six months ended 30 June 2026. This announcement, containing the full text of the 2026 interim report (the "**Interim Report**") of the Company, complies with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") in relation to information to accompany preliminary announcements of interim results.

The Group's interim results for the six months ended 30 June 2026 have been reviewed by the audit and risk management committee of the Company.

This announcement will be published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.pagd.net. The Interim Report for the six months ended 30 June 2026 will be published on the aforesaid websites of the Stock Exchange and the Company and will be sent to the Company's shareholders in due course.

By order of the Board
Ping An Healthcare and Technology Company Limited
Michael Guo
Chairman

Shanghai, the PRC
18 August 2026

As at the date of this announcement, the Board comprises Mr. Mingke He as an executive Director; Mr. Michael Guo, Ms. Xin Fu, Ms. Fangfang Cai and Mr. Ziyang Zhu as non-executive Directors; and Mr. Yunwei Tang, Mr. Tianyong Guo and Dr. Wing Kin Anthony Chow as independent non-executive Directors.

Contents

Corporate Information

Directors

Executive Director

Mr. Mingke He

Non-executive Directors

Mr. Michael Guo (Chairman)
Ms. Xin Fu
Ms. Fangfang Cai
Mr. Ziyang Zhu

Independent Non-executive Directors

Mr. Yunwei Tang
Mr. Tianyong Guo
Dr. Wing Kin Anthony Chow

Audit and Risk Management Committee

Mr. Yunwei Tang (Chairman)
Mr. Tianyong Guo
Ms. Fangfang Cai

Nomination and Remuneration Committee

Mr. Tianyong Guo (Chairman)
Mr. Yunwei Tang
Dr. Wing Kin Anthony Chow
Mr. Michael Guo

Sustainable Development Committee

Dr. Wing Kin Anthony Chow (Chairman)
Mr. Mingke He
Ms. Xin Fu

Authorized Representatives

Mr. Mingke He
Ms. Qin Xu

Joint Company Secretaries

Ms. Qin Xu
Mr. Roy, Sing Yuen Chan

Principal Share Registrar and Transfer Office

Maples Fund Services (Cayman) Limited
PO Box 1093, Boundary Hall
Cricket Square
Grand Cayman, KY1-1102
Cayman Islands

Hong Kong Share Registrar

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17/F, Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

Auditor

Ernst & Young
Certified Public Accountants and Registered PIE Auditor
27/F, One Taikoo Place
979 King's Road, Quarry Bay
Hong Kong

Registered Office

The offices of Maples Corporate Service Limited
PO Box 309
Ugland House
Grand Cayman, KY1-1104
Cayman Islands

Head Office and Principal Place of Business in China

5-8/F, Building B, INNO KIC
No. 298, Guo Xia Road, Yangpu District
Shanghai
PRC

Note: Since 19 August 2026, the Board comprises Mr. Mingke He and Mr. Tongzhuan Xi as executive Directors; Mr. Yougang Zhu and Ms. Yanjun Fan as non-executive Directors; and Mr. Yunwei Tang, Mr. Tianyong Guo and Dr. Kwok Tung Donald Li as independent non-executive Directors, and the composition of the specialized committees under the Board will change correspondingly. Please refer to the announcement in relation to change of Directors and composition of Board committees issued by the Company on 18 August 2026 for details.

Corporate Information

Principal Place of Business in Hong Kong

40th Floor, Dah Sing Financial Centre
248 Queen's Road East
Wanchai
Hong Kong

Principal Correspondent Bank

China Guangfa Bank Co., Ltd.
12/F, One Exchange Square, 8 Connaught Place
Central
Hong Kong

Stock Code

1833

Company's Website

www.pagd.net

Listing Date

4 May 2018

Legal Advisors

As to Hong Kong law:

DLA Piper Hong Kong
25th Floor, Three Exchange Square
8 Connaught Place, Central
Hong Kong

As to PRC law:

Haiwen & Partners
2605, Jing An Kerry Centre Tower 1
No. 1515 Nan Jing West Road
Shanghai
PRC

As to Cayman Islands law:

Maples and Calder (Hong Kong) LLP
26/F, Central Plaza
18 Harbour Road
Wanchai
Hong Kong

Chairman & CEO's Statement

Dear Esteemed Shareholders,

The year 2026 marks the start of the "15th Five-Year Plan" period, ushering in a new phase of high-quality, systematic development for the Healthy China initiative. National health mindset continues to evolve, with the core focus of demand accelerating its shift from disease treatment to full-cycle proactive health management. The multi-tiered medical security system is being steadily refined, with continuous exploration of pathways for deep integration across the medical, pharmaceutical and insurance sectors. Alongside the industrialization of AI in healthcare, the compliant circulation of medical data and the continued advancement of refined medical insurance payment reforms, Internet-based healthcare has formally transitioned from a phase of user acquisition to a cycle of commercialization. Competition in the industry has entered a new era of value-based competition, underpinned by technology, enabled by real-world scenarios, driven by payment mechanisms and fortified by ecosystem-based moats.

As the core flagship of Ping An Group's health and senior care ecosystem, we closely align with policy directions and market demands to act on behalf of payers and integrate providers while integrating and upgrading our "online, in-hospital, at-home and corporate" service matrix. By leveraging AI-powered healthcare technology across all service scenarios and enhancing strategic synergies with Ping An Group's "integrated finance + health and senior care" strategy, we are dedicated to providing a "worry-free, time-saving, and money-saving" one-stop solution for medical, health and senior care services. These efforts have helped us build a managed care model with Chinese characteristics. During the Reporting Period, the Company recorded a total revenue of RMB2,484 million, including revenue from corporate health management of RMB714 million, representing a year-on-year increase of 65.1%. The revenue mix further improved, with corporate health management accounting for 28.7% of total revenue, up 11.5 pps year on year.

Solidifying core ecosystem through commercial insurance enablement and enhancing value-driven operations through insurance + health care synergy. The Company maintains closer collaboration with Ping An Group's integrated financial business. We have built a differentiated membership entitlement matrix tailored to customers' policy types, premium tiers, and senior care needs, which enables precise alignment with diverse customer demands while deeply integrating medical, health, and senior care services with insurance products. Concurrently, the Company is continuously expanding its medical and health benefits portfolio, spanning longevity medicine services, genetic testing, tumor screening and other medical services and resources. Through these diverse, heartwarming service scenarios, the Company increases customer touchpoints and supports scenario-based insurance marketing and customer acquisition. During the Reporting Period, the first-year premium per new life policy of Ping An Home customers increased by 9.7 times[1], demonstrating the continued maturation of the "insurance + health care" synergistic model.

Market-driven growth and unleashing development momentum in corporate health management. As a core strategic segment for optimizing our revenue mix, the corporate health management develops by leveraging a three-dimensional system encompassing channels, products and operations. On the channel front, we deeply integrate with Ping An's ecosystem resources, focusing on high-value large and medium-sized corporate clients and assigning dedicated service teams to them. On the products and services front, we have joined forces with Ping An Group to launch integrated solutions of "commercial insurance + health insurance plans + health care services", while partnering with third parties to enhance the pharmaceutical supply system, covering diverse workplace health needs. On the operational front, we implement proactive and refined operations, developing the "Ping An Circle", an offline service network anchored by a "three-kilometer service radius." We curate and integrate high-quality medical service resources and expand the "Ping An Health Pay" payment service within partner pharmacies, continuously enhancing conversion efficiency, customer stickiness and service reputation. During the Reporting Period, the Company served more than 7,700 paying corporate clients over the past 12 months, representing a year-on-year increase of over 73%. The corporate health management GMV amounted to more than RMB1,790 million.

1 The increase in premium refers to the first year premium ("FYP") per policy of all products with an abovementioned benefit purchased by customers entitled to the benefit divided by the FYP per policy of all such products purchased by customers not entitled, in respect of Ping An Life Insurance's agency and community finance channels, which is the operating result of 1H 2026.

Strengthening scenario-based foundation, with the "online, in-hospital, at-home and corporate" service network serving as the core vehicle for service delivery. The Company continuously iterates and upgrades its "online, in-hospital, at-home and corporate" service network, addressing long-term essential needs such as online consultations, offline medical treatment, workplace health, and home-based senior care. We are building a full-cycle, extensive, high-quality, cost-effective medical service network. **"Online" services**: We completed a comprehensive upgrade of the AI Family Doctor, leveraging an "AI + Physician" collaborative mechanism to cover 100% of Ping An Group's retail customers. During the Reporting Period, AI Doctor was used by over 9.7 million persons. **"In-hospital" services**: We continued to expand our high-quality medical resource network, now partnering with 3,216 Ping An Selected Hospitals, over 3,700 contracted expert doctors, and nearly 245 thousand pharmacies. Leveraging the one-stop Ping An Health Pay settlement system, we have streamlined payment processes both within and outside hospitals, providing users with more convenient experience. **"At-home" services**: We have rolled out a standardized "Ping An Home-based Care" service system. As of the end of the Reporting Period, over 310,000 customers were entitled to home-based senior care services. Concurrently, the Company is strengthening the development of service standards, driving the development of the first domestic association standard document for longevity medicine-based geriatric health service, to fill the gap in industrial standardized service and upgrade home-based senior care and medical services. **"Corporate" services**: We innovated our comprehensive Workplace Clinics solutions to create a new smart health approach of "technology + health care + service," which provides three major services, including integrated audio/video consultations, consultation with renowned doctors, and multi-disciplinary team consultations, precisely aligning with enterprises' demands for health management.

Building a digital-intelligent foundation to empower and consolidate technology foundation and drive inclusive healthcare with enhanced quality and efficiency. Digital intelligence is the Company's core lever for integrating medical resources, upgrading service efficiency, and addressing supply-side bottlenecks, thereby solving the supply-side challenges of ensuring accessible and high-quality medical care. The Company further bolstered its AI capabilities by leveraging Ping An Group's technological strengths and advancing independent R&D efforts, solidifying an integrated closed-loop advantage across "data + models + real-world scenarios." In respect of data, leveraging Ping An Group's four world-leading medical databases, along with nearly 1.5 billion counseling and consultation records, we support the training of medical large model while strictly adhering to compliance requirements. In respect of models, we constantly upgraded our technological foundation – the large multi-modal model, Ping An Medical Master®, and five vertical AI models tailored to key medical scenarios, facilitating smart decision-making throughout the business processes. In respect of real-world scenarios, we deepened our presence in the field of medically necessary care by building "AI + Physician" differentiated service system. During the Reporting Period, the Company constantly upgraded its AI medical product line and AI-enabled MDT assistance platform for complex disease diagnosis, improving clinical service efficiency of related products. AI has contributed to the growth of the Company's gross profit. During the Reporting Period, AI contributed to approximately 4.6% of the Company's gross profit, consistently facilitating the enhancement of service quality and efficiency.

Integrating social responsibility with profitability, our sustainable operations balance public livelihood and commercial value. The Company's various ESG initiatives are being implemented pragmatically and step-by-step, driving the deep integration of the CARE sustainable development strategy into its daily operations and medical services. Internally, we continuously improve the end-to-end management mechanisms for medical quality control, practice standards, and medical data security, thereby solidifying the professional foundation of our overall medical, health, and senior care services. Externally, leveraging our comprehensive service network, we regularly conduct inclusive health education and pro bono online consultations, continuously expanding the boundaries of accessible basic medical services. The Company practices the people-oriented philosophy of "investing in people", establishing standard practical paradigms for workplace health management, and providing actionable references for human-centric operations in the industry. While creating corporate value through robust operations, we steadfastly uphold our social responsibility to enhance public livelihoods, achieving the synergistic growth and advancement of both commercial and public value.

With persistent efforts, we have strengthened our core competitiveness through long-term dedication. Seizing the historic opportunities from the rapid development of China's medical and health industry, as the core flagship of Ping An Group's health and senior care ecosystem and a consolidated subsidiary of Ping An Group, we will continue to rely on our "online, in-hospital, at-home and corporate" service system and strengths in AI technologies to deepen synergies and mutual enablement with Ping An Group. On the one hand, we will deepen the development of our commercial insurance enablement, iteratively upgrade the health and senior care product matrix, and implement tiered and refined customer operations to enable Ping An Group's integrated finance business to gain differentiated competitiveness. On the other hand, we will deepen our corporate health management, integrate online and offline operations, retain customer traffic, and enhance user stickiness. The Company will constantly integrate its "online, in-hospital, at-home and corporate" service network under a user demand-oriented approach, and build a full-scenario service system with multiple touchpoints, aiming to deliver closed-loop online-merge-offline service experience. We will collaborate with industry partners to co-build a health industry ecosystem, continuously apply AI capabilities to optimize the medical and insurance service experience, and give back to users, shareholders, and society with smarter, more precise, and compassionate health services, remaining steadfast in our commitment to creating long-term, sustainable value for the Digital China and the Healthy China initiatives.

Michael Guo
Chairman of the Board

Mingke He
Chief Executive Officer

18 August 2026

Management Discussion and Analysis

As the core flagship of Ping An Group's health and senior care ecosystem, the Company consistently integrates and upgrades its "online, in-hospital, at-home and corporate" service matrix as Ping An Group further advances the "integrated finance + health and senior care" dual-pronged strategy. The Company provides "worry-free, time-saving, and money-saving" one-stop medical, health, and senior care services, forging closed-loop synergies with Ping An Group's integrated finance business to build a managed care model with Chinese characteristics. As collaborative synergies between the Company and Ping An Group grow stronger, the long-term strategic value of mutual enablement is becoming increasingly evident.

2026 marks the beginning of a new phase of high-quality development of China's health industry under the 15th Five-Year Plan, as well as a critical time in advancing the "Healthy China 2030" strategy. Policy support for the health care sector continues to strengthen, accelerating the transition from policy design to practical implementation. In health care, local governments released a series of detailed implementation rules in the first half of 2026 in response to the *Guiding Opinions on Promoting and Regulating the Application and Development of "Artificial Intelligence + Health Care,"* jointly issued by China's National Health Commission and four other authorities at the end of 2025. These implementation rules offered clearer policy guidance and specified use scenarios for medical AI, driving its large-scale application. In senior care services, the state steadily advanced senior care reforms, reinforcing the foundational role of home-based senior care. In the first half of 2026, a number of industry standards for integrated health and senior care services were successively introduced. During the same period, China's first domestic association standard document for longevity medicine-based geriatric health service, the *Standards for Geriatric Health Service Based on Longevity Medicine* was released, bolstering technology-enabled home-based senior care, and chronic disease management and home-based rehabilitation services for seniors. In synergistic development of health care and commercial insurance, the "insurance + health care" synergistic mechanism was constantly improved, with integrated settlement progressively rolled out across regions.

The Company boasts abundant payer resources, extensive service networks, cutting-edge healthtech capabilities, and strong support from Ping An Group's ecosystems. Building on these core competitive advantages and the sustained policy support, the Company consistently develops a specialized, comprehensive, high-quality and one-stop "health and senior care" services platform, providing users with "worry-free, time-saving, and money-saving" health and senior care services.

Key Financial Data

	Six months ended 30 June		
	2026	2025	Year-on-year change
	RMB'000	RMB'000	
Revenue	**2,483,833**	2,502,193	-0.7%
Cost of sales	**(1,527,163)**	(1,662,484)	-8.1%
Gross profit	**956,670**	839,709	13.9%
Selling and marketing expenses	**(386,069)**	(381,020)	1.3%
Administrative expenses	**(405,512)**	(371,947)	9.0%
– Including: research and development expenses	**(144,446)**	(161,633)	-10.6%
Other income	**13,125**	16,468	-20.3%
Impairment losses on financial and contract related assets	**(1,011)**	(30,190)	-96.7%
Other gains, net	**38,882**	1,848	2,004.0%
Finance income, net	**44,612**	60,033	-25.7%
Share of profits and losses of associates	**(10,044)**	1,359	N/A
Profit before tax	**250,653**	136,260	84.0%
Income tax expense	**(30,880)**	(1,352)	2,184.0%
Profit for the period	**219,773**	134,908	62.9%
Profit attributable to:			
– Owners of the parent	**219,332**	134,164	63.5%
– Non-controlling interests	**441**	744	-40.7%
Non-IFRS measure:			
Adjusted net profit	**226,800**	164,749	37.7%

- The Company consistently advanced the "insurance + health care" synergistic model, focusing on upgrading medical, health, and senior care products and services to strengthen the closed-loop synergy with the Group's integrated finance business. Meanwhile, the Company promoted the development of corporate health management. During the Reporting Period, the Company recorded a total revenue of RMB2,483.8 million.

- Specifically, revenue from corporate health management reached RMB713.8 million, representing a year-on-year increase of 65.1%. The revenue mix further improved, with corporate health management accounting for 28.7% of total revenue, up 11.5 pps year on year. Revenue from commercial insurance enablement reached RMB1,584.4 million, remaining largely unchanged year on year.

- The Company's business quality constantly improved, with gross profit reaching RMB956.7 million, representing a year-on-year increase of 13.9%.

- The Company continued to invest in technology research and development ("R&D"), further enhancing its capabilities in applied AI and digital operations. To further expand its business scale, the Company moderately increased investment in its core business, leading to a slight increase in total expenses. Total expenses accounted for 31.9% of revenue, up 1.8 pps year on year. Specifically, administrative expenses accounted for 16.3% of revenue, up 1.5 pps year on year; and selling and marketing expenses accounted for 15.5% of revenue, up0.3 pps year on year.

- Driven by constantly improved revenue mix and business quality, the Company recorded a profit of RMB219.3 million attributable to shareholders of the parent company, up 63.5% year on year. Adjusted net profit stood at RMB226.8 million, up 37.7% year on year.

Analysis of Main Business Operations

During the Reporting Period, as the core flagship of Ping An Group's health and senior care ecosystem and a consolidated subsidiary of Ping An Group, the Company further strengthened collaboration with Ping An Group. For commercial insurance enablement, the Company consistently advanced the "insurance + health care" synergistic model, focusing on upgrading medical, health, and senior care products and services. By doing so, the Company helped insurers enhance their product competitiveness and boost customer acquisition, retention, and value, thereby consistently supporting Ping An Group's integrated finance business. For corporate health management, the Company consistently expanded its corporate client base in collaboration with Ping An Group, offering integrated solutions of "commercial insurance + health insurance plans + health care services." By constantly diversifying products and services, and strengthening conversion via operations, the Company helped enterprises improve employee health outcomes and workplace well-being.

Moreover, the Company consistently advanced its extensive, high-quality, cost-effective "online, in-hospital, at-home and corporate" service system, offering full-scenario, full-cycle, online-merge-offline and closed-loop health management. To strengthen its technological capabilities, the Company further promoted AI enablement by seamlessly integrating AI with physicians. The Company leveraged AI to drive sustained growth in user coverage and engagement, gross profit, and cost efficiency while ensuring heartwarming and professional services.

1. Payers

Commercial insurance enablement

Ping An Group makes its sustained efforts to advance the "integrated finance + health and senior care" strategy. As the core flagship of Ping An Group's health and senior care ecosystem, the Company maintains closer collaboration with Ping An Group's integrated finance business. During the Reporting Period, the Company further supported payers including Ping An Life Insurance, Ping An Property & Casualty Insurance, Ping An Health Insurance, and Ping An Bank, providing 24/7 online-merge-offline one-stop, proactive health and senior care services for the Group's retail customers. This enables Ping An Group's integrated finance business to gain differentiated product competitiveness and boost customer acquisition, retention, and value. During the Reporting Period, the first-year premium per new life policy of Ping An Home customers increased 9.7 times[1].

1 The increase in premium refers to the first year premium ("FYP") per policy of all products with an abovementioned benefit purchased by customers entitled to the benefit divided by the FYP per policy of all such products purchased by customers not entitled, in respect of Ping An Life's agency and community finance channels, which is the operating result of 1H 2026.

During the Reporting Period, the Company consistently advanced the "insurance + health care" synergistic model, focusing on upgrading products and services. Leveraging its membership service system deeply integrated with insurance products, the Company further upgraded and diversified membership benefits based on policy types and premium tiers, thereby helping to enhance competitive differentiation of insurance products and strengthen customer retention. For wealth management insurance customers, the Company further upgraded its multi-tiered membership system. Based on the existing product and service portfolios, the Company launched the "Medical Visit Access" health service plan in collaboration with Ping An Life Insurance, providing customers with cutting-edge diagnostics and full-process medical care resources. By doing so, the Company established an end-to-end "health + medical" service system. For high-value customers, the Company launched the new "Private Membership Club," integrating premium medical resources such as cutting-edge diagnostics (e.g. tumor genetic testing and PET/MR imaging) and advanced therapies. Additional services like chronic disease management, critical illness management, psychological counseling are also provided to establish a medical and health service system across all scenarios. For pension insurance customers, the Company further upgraded its home-based senior care service system. During the Reporting Period, the Company, in collaboration with Ping An Life Insurance, launched the "Ping An Home" service brand, facilitating a transition from reactive response to proactive health management. As of 30 June 2026, over 310,000 customers were entitled to home-based senior care services.

Moreover, the Company constantly diversifies its marketing and customer acquisition scenarios. Catering to the needs of insurance, banking, and other financial service customers, the Company partners with qualified institutions to provide medical services and resources, spanning longevity medicine, genetic testing, tumor screening, fecal microbiota transplantation, cutting-edge therapies, and advanced pharmaceuticals and medical devices. Through these diverse service scenarios, the Company increases customer touchpoints and supports scenario-based insurance marketing and customer acquisition.

Corporate health management

Leveraging the capabilities built up by serving Ping An Group's retail financial customers, the Company has been steadily expanding its presence into the corporate client segment. Adhering to the "worry-free, time-saving, and money-saving" service philosophy, the Company is committed to providing professional, comprehensive, high-quality, one-stop corporate health management solutions that help enterprises improve employee health outcomes and workplace well-being.

In respect of client base expansion, the Company consistently strengthens its collaboration with corporate clients accessed via Ping An Group's channels, with a focus on the large and medium-sized enterprises with a strong ability and willingness to pay. In this way, the Company delivers comprehensive health management solutions to their employees. During the Reporting Period, the Company served more than 7,700 paying corporate clients over the past 12 months, a year-on-year increase of over 73%. The corporate health management GMV amounted to more than 1,790 million.

The Company leverages diverse product and service offerings to strengthen conversion via online and offline operations. The Company collaborates with Ping An Group to launch integrated solutions of "commercial insurance + health insurance plans + health care services," providing corporate employees with comprehensive, premium, and cost-effective health management services. In respect of online operation, the Company consistently expands product and service offerings by integrating third-party platforms and leveraging their fulfillment capabilities. By doing so, the Company helps meet corporate employees' needs for medical and health management services, thereby improving service experience. Moreover, with authorization from users, family doctors provide proactive, end-to-end health management based on corporate employees' health records, enabling precise matching of products and services and effectively improving the service utilization rate and health intervention outcomes. In respect of offline operation, the Company provides corporate clients with comprehensive medical and health services through Workplace Clinics and regular corporate activities, including health screening, medical visit assistance, and health management. During the Reporting Period, the Company provided enterprise-specific solutions by assigning dedicated service teams to key corporate clients and customizing benefits for their employees. Moreover, the Company provides corporate employees with proactive medical management covering specialized diagnosis and treatment, distinctive medicines, and unique health management services. During the Reporting Period, the Company consistently developed the "Ping An Circle", an offline service network centered on corporate clients' workplaces and connecting nearby health service resources within a three-kilometer radius. By integrating high-quality pharmacies and other service outlets into the network, the Company provides premium "worry-free, time-saving, and money-saving" service experience for corporate employees. In addition, the Company collaborated with Ping An Group to consistently strengthen the capabilities of corporate health service specialists, providing enterprises with all-round, exclusive services to improve client satisfaction.

Service highlights:

Positioned as convenient health service hubs within a three-kilometer radius of corporate workplaces, "Ping An Circle" outlets integrate offline service outlets such as high-quality pharmacies. Leveraging "Ping An Circle's" offline service network, the Company provides exclusive employee benefits and special offers at key partner outlets. Corporate employees visiting these outlets can enjoy exclusive offers on selected partner products, making corporate health benefits tangible and easily accessible. As of 30 June 2026, the Company had over 500 "Ping An Circles" in operation, comprising over 10,000 partner outlets. The Company also established in-depth partnerships with leading chain pharmacies nationwide. By connecting online consultations with offline outlet services, the Company provides corporate employees with exclusive services and benefits including health consultation, report interpretation, chronic disease management, medication use guidance, and medicine benefits. In this way, the Company promotes corporate employees' physical and mental well-being and contributes to the high-quality, sustainable development of corporate clients.

2. "Online, in-hospital, at-home and corporate" services

The Company consistently advanced its extensive, high-quality, cost-effective "online, in-hospital, at-home and corporate" service system. During the Reporting Period, the Company further expanded its service network and improved service quality by actively integrating third-party service providers to diversify service and product offerings. The Company also collaborated with leading domestic and overseas pharmaceutical companies to provide wider access to high-quality pharmaceuticals and medical devices. In this way, the Company better addressed users' medical and health management needs, thereby improving customer satisfaction and its reputation for service quality.

"Online" services

The Company consistently aggregates customer traffic from Ping An Group's health and senior care ecosystem, as well as from external enterprises. The Company grows its user base and engages users through "online" services. In this way, the Company provides full-scenario, closed-loop services via multiple touchpoints.

The Company consistently upgrades its multi-tiered family doctor system to provide policyholders and corporate employees with full-cycle, proactive medical and health management services. During the Reporting Period, the Company launched the "integrated comorbidity management" service targeting users with chronic conditions. Based on each user's specific chronic conditions and individual health indicators, the Company sets up a dedicated service team consisting of case managers, physicians, psychological counselors, nutritionists, and rehabilitation therapists. The team monitors and manages the user's lifestyle, disease state and medication use, and conducts precise and dynamic health interventions to genuinely improve the user's health.

Moreover, the Company's "AI + Physician" services covered 100% of Ping An Group's retail customers, providing 24/7 heartwarming, professional online consultation services.

Service case:



An insurance customer of Ping An Group had multiple chronic diseases, such as hypertension, atherosclerosis, hyperlipidaemia, and diabetes. As part of the customer's exclusive medical benefits, the Company provided an integrated "comorbidity management" program comprising comprehensive medical and health services. Under the program, a case manager monitored changes in the customer's physical indicators, and coordinated and periodically adjusted the overall health management plan. A psychological counselor proactively provided counseling to help improve the customer's sleep quality. In addition to providing daily dietary advice, a nutritionist reviewed photographs of the customer's meals and provided professional feedback. Based on the customer's medical and medication records and taking multiple chronic conditions into account, a chronic disease physician provided guidance on concomitant medications. A rehabilitation therapist developed a personalized exercise program based on the customer's physical conditions and exercise tolerance, provided daily reminders to record exercise activities, and guided the customer on proper exercise techniques. Following this multi-dimensional health management program, the customer achieved measurable improvements in all physiological indicators and health status.

"In-hospital" services

The Company consistently expands its offline service network. The Company had about 50,000 in-house and contracted external doctors as of 30 June 2026. Among them were over 3,700 contracted expert doctors, including 9 academicians/national TCM masters, over 820 hospital presidents/vice hospital presidents/department heads/discipline leaders, offering tip-top services such as MDT consultations, outpatient care, and inpatient care. The Company partnered with 3,216 Ping An Selected Hospitals, covering 1,732 or 92.3% of 3A hospitals. Ping An Selected Hospitals provide services including appointments, bed arrangement, surgeries, examinations, and rehabilitation, meeting all-around, full-cycle customer needs for medical services. The Company partnered with nearly 245 thousand pharmacies, and maintained partnerships with over 4,600 health checkup service providers.

Furthermore, for scenarios including offline medicine purchases by members of corporate health management programs, the Company consistently advances the "Ping An Health Pay" service through its proprietary direct payment system, which enables QR code payments at 149 thousand pharmacies nationwide, a significant increase year to date. Moreover, the Company piloted convenient payment services for offline medical visits at hospitals[2]. Customers can enjoy an experience of zero upfront payment and quick claims settlement. While providing users with more convenient experience, the Company enables closed loops of services and data. Going forward, the Company will further expand the service coverage.

Service case:

Ms. Zhang, an employee of a large enterprise, is covered by a corporate health insurance plan. One day, Ms. Zhang visited a contracted pharmacy in "Ping An Circle's" service network downstairs at her office building due to a sore swollen throat. She completed a rapid flu screening on-site and then selected the appropriate medication. At the cashier, Ms. Zhang logged into the app and presented the "Ping An Health Pay" QR code. Since the medication she purchased was in the coverage catalog, the corresponding cost was directly deducted from the employer's dedicated health care fund account, requiring no out-of-pocket payment. Throughout the convenient drug purchase process, Ms. Zhang enjoyed significantly improved service experience featuring "no reimbursement needed, one-click payment."

2 SHI designated public hospitals of Grade 2 and above nationwide, or other designated hospitals.

"At-home" services

The Company consistently strengthens its "at-home" service capabilities across scenarios including medical services, health management, safety, and care. During the Reporting Period, the Company and Ping An Life Insurance jointly launched the "Ping An Home" service brand by leveraging Ping An Group's strengths in "integrated finance + health and senior care," and also rolled out the flagship "7 Benefits"[3] covering sleep, nutrition and exercise. Anchored by "AI concierge, life concierge and doctor concierge" services, Ping An Home offers comprehensive proactive health management services via proactive management, a focus on essential needs, and visible workflows.

Regarding medical services, the Company integrates premium resources to provide full-cycle medical services before, during, and after medical treatment. Regarding health management, the Company provides 24/7 proactive health management services. Regarding safety, the Company has developed global emergency assistance services in collaboration with Ping An Group. Regarding professional care, the Company seamlessly integrates three care scenarios, namely inpatient care, home care, and senior care institution recommendation, to meet personalized care needs. The Company provided home-based senior care services in 140 cities nationwide as of 30 June 2026.

"Corporate" services

In the corporate health management scenario, the Company offers employees a range of corporate services, including professional health screening, medical consultation and treatment, and health management to support enterprises in building healthy workplaces. During the Reporting Period, the Company innovated its comprehensive Workplace Clinics solutions to create a new smart health approach of "technology + health care + service." By integrating audio/video consultations, consultations with renowned doctors, and MDT consultations, this approach enables online diagnosis and treatment for common and frequently-occurring diseases. Employees can access high-quality medical resources and comprehensive health protection without leaving their workplaces.

3 The "7 Benefits" are sleep management, nutrition management, functional improvement, comorbidity management, medical visit guidance, global medical consultation and drug sourcing and smart guard.

Service case:

The Company partnered with Lilly China, a world-leading pharmaceutical company, to host an on-site health event at a large enterprise, piloting an innovative model of "insurance + health care + pharmaceutical companies". Leveraging the Company's diverse health care resources and Lilly's specialized weight management services, the event featured a series of customized interactive health zones. Employees can understand their health through health challenges on interactive screens, motion-sensing games, smart health checks and so on. Moreover, online doctors and health advisers offered professional, personalized weight management, diet and fitness recommendations based on Lilly's science-based weight management programs, helping employees with healthy weight loss. In addition, employees can get an exclusive package of services by scanning a QR code at the event. By extending health management into everyday life, the Company transitioned corporate health management from one-off events to sustained, routine engagement.

Moreover, the Company enhances service quality and drives industry upgrade by strengthening the development of service standards. During the Reporting Period, Chinese Aging Well Association released and implemented the *Standards for Geriatric Health Service Based on Longevity Medicine* (T/CAWAORG 058 – 2026), marking the first domestic association standard document for longevity medicine-based geriatric health service. The standards were developed by a panel of 26 leading experts in geriatrics and general medicine, in collaboration with 23 3A hospitals and senior care institutions. The Company, as a core member of the drafting team, was deeply engaged in the entire formulation process, helping to fill the gap in standardized longevity medicine service in China and upgrade home-based senior care and medical services through a standardized framework.

3. Technology Enablement

During the Reporting Period, the Company further bolstered its AI capabilities by advancing independent R&D efforts and leveraging Ping An Group's technological strengths. Through deeper integration of data, models, and real-world scenarios, the Company promoted the deployment of AI across key medical and health scenarios, yielding increasingly significant outcomes in AI enablement.

In respect of data, the Company boasts a unique advantage in closed-loop health care and insurance data. Leveraging Ping An's four world-leading medical databases[4], nearly 1.5 billion counseling and consultation records, and so on, the Company trained medical large AI models by processing and using the aforementioned massive data in strict compliance with relevant laws and regulations.

In respect of models, the Company constantly upgraded its technological foundation – the large multi-modal model Ping An Medical Master®—and five vertical AI models tailored to key medical scenarios, facilitating smart decision-making throughout the business processes.

In respect of real-world scenarios, the Company deepened its presence in the field of medically necessary care by building differentiation advantages through an "AI + Physician" approach, delivering professional and heartwarming services to users while enabling proactive, continuous health management. During the Reporting Period, the Company constantly upgraded its medical AI product line. The "AI + Physician" model has been fully integrated into Ping An Group's app matrix, covering 100% of its retail customers. Over 11.3 thousand diseases can be precisely diagnosed by AI Doctor, with an accuracy rate of nearly 96% in AI Doctor-aided diagnosis/treatment. At the same time, the Company further upgraded its AI-enabled MDT assistance platform for complex disease diagnosis, expanding from its original application in breast cancer to gastric cancer. The AI-enabled MDT platform has achieved an accuracy rate of nearly 90% in diagnosing complex diseases and formulating treatment plans, paving the way for expansion into a broader range of conditions.

The Company consistently bolstered its AI capabilities and applications, achieving notable results in AI enablement. Powered by AI, the Company significantly expanded its service coverage and usage. During the Reporting Period, AI Doctor was used by over 9.7 million persons. AI has contributed to the growth of the Company's gross profit. During the Reporting Period, AI contributed approximately 4.6% of the Company's gross profit.

Going forward, the Company will further capitalize on its unique strengths in closed-loop health care and insurance data, "AI + Physician" service packages, and online-merge-offline one-stop medical scenarios to accelerate the application of AI large models across a broader range of scenarios, including professional medical services, and product and service innovation under the "insurance + health care" synergistic model.

4 Including individual and corporate information, hospital and physician information, disease directories, and pharmaceutical and medical device information databases.

Long-term Strategies and Management Outlook

With the development of China's social economy, the growing health awareness among residents, and the accelerating pace of aging, the public demand for high-quality medical services has been on the rise. The health care industry is poised to embrace new development opportunities. As commercial insurers and enterprises are emerging as important payers in China's medical and health industries, the multi-tiered health care security system will further expand.

As the core flagship of Ping An Group's health and senior care ecosystem and a consolidated subsidiary of Ping An Group, the Company boasts an "online, in-hospital, at-home and corporate" service system and an advantage in AI technologies. The Company will consistently strengthen mutual enablement and synergies with Ping An Group, aiming to build the Health Maintenance Organization model with Chinese characteristics. Furthermore, by leveraging the strengths in service networks, operational efficiency and data accumulated through serving internal clients, the Company constantly enables corporate clients and other external market players with its professional health management capabilities.

In respect of commercial insurance enablement, the Company will further strengthen product innovation and scenario integration under the "insurance + health care" synergistic model, upgrade products and services, enhance end-to-end service capabilities, and promote tiered customer operations. By doing so, the Company will support Ping An Group's integrated finance business in pursuing competitive differentiation, and boosting customer acquisition, retention and value. In respect of corporate health management, the Company will work with Ping An Group to accelerate client acquisition, scaling up the corporate health management and strengthening conversion via online/offline operations. While aggregating traffic from all channels, the Company will further strengthen customer operation and boost customer retention and value throughout their lifecycle.

In respect of the development of service capabilities, the Company will constantly integrate its "online, in-hospital, at-home and corporate" service network under a user-oriented approach, and build a full-scenario service system with multiple touchpoints, aiming to deliver closed-loop online-merge-offline service experience. Moreover, the Company will upgrade its supply chain management system to create a mutually beneficial ecosystem with industry partners. The Company will constantly enhance the development and application of technological capabilities, driving the deployment of AI in more medical service scenarios and "insurance + health care" synergistic scenarios. By leveraging AI to enhance service efficiency and optimize service experience, the Company will build a smarter, more accurate, and heartwarming medical and health service system.

Going forward, the Company will keep striving to create sustained long-term value for users, shareholders, and society. The Company will provide users with high-quality medical and health services, deliver more sustainable and stable returns to shareholders, and unswervingly support the Digital China and the Healthy China initiatives.

Financial Review

Revenue

	Six months ended 30 June		
	2026	2025*	Year-on-year change
	RMB'000	RMB'000	
Revenue:			
Commercial insurance enablement	**1,584,427**	1,584,313	0.0%
Corporate health management	**713,842**	432,361	65.1%
Others	**185,564**	485,519	-61.8%
Total of revenue	**2,483,833**	2,502,193	-0.7%

* Data information in the same period of 2025 has been restated.

During the Reporting Period, the Company recorded revenue of RMB2,483.8 million, representing a decrease of 0.7% from RMB2,502.2 million in the same period of 2025. The Company continuously enhanced the "insurance + health care" synergistic model, focused on improving and iterating medical, health, and senior care products and services, and strengthened closed-loop synergies with the Group's integrated finance business. The Company's revenue mix was further optimized by increasingly promoting the development of corporate health management, which increased by 65.1% year on year to RMB713.8 million.

Gross Profit and Gross Margin

During the Reporting Period, the business quality of the Company continued to improve with gross profit amounting to RMB956.7 million, representing an increase of 13.9% from RMB839.7 million in the same period of 2025. Gross margin recorded by the Company was 38.5%, up 4.9 percentage points as compared to the same period in 2025.

Selling and Marketing Expenses

Selling and marketing expenses amounted to RMB386.1 million in the first half of 2026, representing an increase of 1.3% from RMB381.0 million in the first half of 2025. The selling and marketing expense ratio was 15.5%, representing a year-on-year increase of 0.3 percentage point. While continuously enhancing input-output management and resource allocation efficiency, the Company actively positioned itself for new business expansion.

Administrative Expenses

Administrative expenses amounted to RMB405.5 million in the first half of 2026, representing an increase of 9.0% from RMB371.9 million in the first half of 2025. The administrative expense ratio was 16.3%, representing a year-on-year increase of 1.5 percentage points. As the scale of the corporate health management continued to expand, the functions of operation services and supplier management were strengthened, which increased such expenses.

Other Income

Other income amounted to RMB13.1 million in the first half of 2026, representing a decrease of 20.3% from RMB16.5 million in the first half of 2025, which was mainly attributable to the fluctuation in income on short-term investments placed with banks and a decrease in government grants received during the period.

Other Gains, Net

Other net gains amounted to RMB38.9 million in the first half of 2026, compared with other net gains of RMB1.8 million in the first half of 2025, which was mainly attributable to provision for impairment loss on investments in associates of RMB40.1 million in the first half of 2025, while there were no indications of further impairment during the Reporting Period.

Finance Income, Net

Net finance income amounted to RMB44.6 million in the first half of 2026, representing a decrease of 25.7% from RMB60.0 million in the first half of 2025, which was mainly attributable to a decrease in interest income of the Company.

Net Profit for the Period and the Non-IFRS Measure: Adjusted Net Profit

Our net profit for the first half of 2026 amounted to RMB219.8 million, compared with net profit of RMB134.9 million recorded in the first half of 2025. To supplement our consolidated financial information presented in accordance with IFRS, we also adopted the "adjusted net profit" which is not a required standard under IFRS or which is presented not in accordance with IFRS requirements as an additional financial measure. For the purpose of this interim report and future interim reports, the "adjusted net profit" may be used in exchange with the "net profit not under GAAP". We believe that this additional financial measure is useful for comparing our operating performance between different periods and different companies by eliminating the potential impact of items which, in the opinion of our management, are not indicative of our operating performance. We also believe that the additional measure can provide investors and other individuals with meaningful information, allowing them to understand and assess our consolidated operating results in the same way as our management. However, the "adjusted net profit" presented by us may not necessarily be comparable with the similar measures presented by other companies. Such non-IFRS measure has a limitation as an analytical tool. Thus, a view should not be held that it is independent from or can replace the analysis of our operating results or financial position presented in accordance with IFRS. After excluding the impact of share-based payments and net foreign exchange losses, the adjusted net profit in the first half of 2026 amounted to RMB226.8 million, compared with the adjusted net profit of RMB164.7 million in the first half of 2025. The following table sets forth the adjusted net profit for the six months ended 30 June 2026 and 2025 as the most directly comparable financial measure (namely, net profit for the period) calculated and presented in accordance with IFRS:

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
Net profit for the period	**219,773**	134,908
Excluding:		
Share-based payments	**4,747**	5,325
Net foreign exchange losses	**2,280**	24,516
Adjusted net profit	**226,800**	164,749

Liquidity and Financial Resources

Our cash and other liquid financial resources as of 30 June 2026 and 31 December 2025 were as follows:

	30 June 2026 RMB'000	31 December 2025 RMB'000
RMB	**4,382,319**	1,658,745
USD	**32,658**	12,579
HKD	**6,461**	48,748
	4,421,438	1,720,072

Cash and cash equivalents include cash in hand and at banks, bank deposits, and other short-term highly liquid deposits with original maturities of three months or less. Our cash and cash equivalents are mostly denominated in RMB.

As of 30 June 2026, our total available funds were RMB9,641.4 million, including cash and cash equivalents of RMB4,421.4 million, restricted cash of RMB975.8 million, term deposits of RMB588.7 million, and financial assets of RMB3,655.4 million. The financial assets purchased mainly from Ping An Asset Management, Ping An Wealth Management and others, have effectively improved the yields and liquidity of the Company's idle funds.

Cash flows for the six months ended 30 June 2026 and six months ended 30 June 2025 were as follows:

	Unaudited Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Net cash generated from operating activities	**25,392**	63,557
Net cash generated from investing activities	**2,699,207**	4,671,325
Net cash used in financing activities	**(21,245)**	(3,924,273)
Net increase in cash and cash equivalents	**2,703,354**	810,609
Cash and cash equivalents at the beginning of the period	**1,720,072**	2,044,653
Effects of exchange rate changes on cash and cash equivalents	**(1,988)**	(2,250)
Cash and cash equivalents at the end of the period	**4,421,438**	2,853,012

Net cash generated from investing activities mainly included payments of RMB1,848.3 million for subscription of financial assets at fair value through profit or loss and term deposits with initial term of over three months and proceeds of RMB4,554.3 million from redemption of financial assets at fair value through profit or loss and term deposits with initial term of over three months.

Treasury Policy

Our cash arises almost exclusively from equity funding. Such cash can only be invested in relatively liquid and low-risk instruments such as bank deposits or money market instruments. The primary objective of our investments is to generate finance income at a yield higher than the interest rate of current bank deposits, and to maintain liquidity.

Capital Expenditure

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
Purchase of property, plant and equipment, intangible assets and other assets	**6,993**	3,582

Our capital expenditures primarily comprised the expenditure for purchasing property, plant and equipment (mainly office and electronic equipment).

Foreign Exchange Risk

For the six months ended 30 June 2026, we mainly operated our businesses in China with most of the transactions settled in RMB, the functional currency of our Company. Foreign exchange risk is the risk of incurring losses due to changes in foreign exchange rates. Fluctuations in the exchange rates between RMB and other currencies that we use to conduct our business operations may affect our financial position and operating results. The foreign exchange risk assumed by us primarily arises from movements in the USD/RMB and HKD/RMB exchange rates. Considering foreign exchange risk potentially brought by the fluctuations in the exchange rates, the Company completed preparation for utilization of financial instruments in 2020 and held such instruments in 2026 in response to the fluctuations in the exchange rates at any time.

Pledge of Assets

As of 30 June 2026, none of our assets were pledged.

Provisions

As at 30 June 2026, the Group was the defendant in certain outstanding litigations. Combining with fact and the progress, as well as the opinions of the internal and external legal counsels, the Group recognized the estimated losses from such litigations and disputes as provisions.

Dividend

We did not pay or declare any dividend for the six months ended 30 June 2026.

Bank Loans and Other Borrowings

As at 30 June 2026, except for the borrowings of RMB10,500,000 obtained by Pingan Yingjian, a subsidiary of the Company, from its shareholder, Yingjian Enterprise Management Consulting, we did not have any outstanding loans. As at 30 June 2026, the Group's gearing ratio was 22.98%, which was calculated by dividing the Group's total liabilities by its total assets as at 30 June 2026.

Significant Investments Held

As at 30 June 2026, we did not hold any material investments with a value of 5% or more of the Group's total assets.

Future Plans for Material Investments or Capital Assets

As of 30 June 2026, we did not have any future plans for material investments or capital assets.

Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

For the six months ended 30 June 2026, we did not carry out any material acquisitions and disposals of subsidiaries, associates and joint ventures.

Employee and Remuneration Policy

The Group had a total of 1,586 employees as of 30 June 2026, the majority of whom were based in various cities in the PRC, including Shanghai, Shenzhen, Guangzhou, Hefei, Beijing and Qingdao. The Group has established a remuneration system of "cash salary + benefit + long-term incentive." Remuneration is determined with reference to market conditions and individual employees' performance, qualifications and experience. In line with the performance of the Company and individual employees, a competitive remuneration package is offered to retain employees, including salaries, discretionary bonuses and benefit plans. Employees of the Company are eligible participants of the Pre-IPO employee share option scheme, details of which are set out in the Prospectus. In addition to on-the-job training, we have also adopted training policies to provide a wide range of in-house and external trainings for employees. During the Reporting Period, the relationship between the Company and its employees was always stable. We did not experience any strikes or other labor disputes which materially affected our business activities.

Directors' and Chief Executives' Interests and Short Positions in the Shares, Underlying Shares and Debentures

As at 30 June 2026, the interests and short positions of the Directors and chief executives of the Company in the Shares, underlying Shares and debentures of the Company or its associated corporations, within the meaning of Part XV of the SFO, which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or were recorded in the register required to be maintained by the Company under section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

Long positions/short positions in the Shares of the Company

Name of Director	Nature of interest	Number of Shares held	Long positions/ short positions	Approximate percentage of interest in the Company (1)
Mr. Mingke He (2)	Beneficial owner	1,162,433	Long positions	0.05%

Notes:

(1) The calculation is based on the total number of Shares in issue of 2,161,443,720 of the Company as of 30 June 2026.

(2) As of 30 June 2026, depending on the performance of the Group as a whole and individual performance, Mr. Mingke He was entitled to a maximum of 1,278,676 Shares pursuant to the Employee Incentive Scheme, where no Share was held upon exercise of EIS Options under the Employee Incentive Scheme.

Long positions/short positions in the shares of associated corporations of the Company within the meaning of the SFO:

Name of Director	Name of associated corporation	Nature of interest	Number of shares and/or underlying shares of Ping An Group	Long positions/ short positions	Approximate percentage of interest in Ping An Group [1]
Michael Guo [2]	Ping An Group	Beneficial owner	170,506 A shares	Long positions	0.00%
		Other [2]	103,368 A shares		
			895,703 H shares		
Xin Fu [3]	Ping An Group	Beneficial owner	137,206 A shares	Long positions	0.00%
		Other [3]	139,893 A shares		
			672,209 H shares		
Fangfang Cai [4]	Ping An Group	Beneficial owner	790,124 A shares	Long positions	0.01%
		Other [4]	815,519 A shares		
			677,667 H shares		

Notes:

(1) The calculation is based on the total number of shares in issue of Ping An Group as of 30 June 2026, including 10,660,065,083 A shares and 7,447,576,912 H shares.

(2) 103,368 A shares and 895,703 H shares of Ping An Group were granted to Mr. Michael Guo as part of his payroll under the Long-term Service Plan of Ping An Group. Such shares are held by a trust and will be vested upon his retirement subject to certain conditions.

(3) 139,893 A shares and 672,209 H shares of Ping An Group were granted to Ms. Xin Fu as part of her payroll under the Long-term Service Plan of Ping An Group. Such shares are held by a trust and will be vested upon her retirement subject to certain conditions.

(4) 815,519 A shares and 677,667 H shares of Ping An Group were granted to Ms. Fangfang Cai as part of her payroll under the Long-term Service Plan of Ping An Group. Such shares are held by a trust and will be vested upon her retirement subject to certain conditions.

Save as disclosed above, as of 30 June 2026, so far as known to the Directors, none of the Directors or chief executives of the Company had or was deemed to have interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations, within the meaning of Part XV of the SFO, which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or were recorded in the register required to be maintained by the Company under section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

Substantial Shareholders' Interests and Short Positions in the Shares and Underlying Shares of the Company

As of 30 June 2026, so far as known to the Directors, the following persons (other than the Directors or chief executives of the Company) had interests or short positions in the Shares or underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under section 336 of the SFO, or were, directly or indirectly, interested in 5% or more of the Shares of the Company:

Long positions/short positions in the Shares of the Company

Name of Shareholder	Nature of interest	Number of Shares held	Long positions/ short positions	Approximate percentage of interest in the Company [(1)]
An Ke Technology Company Limited [(2)]	Interest in controlled corporations	1,160,994,737	Long positions	53.71%
Shenzhen Ping An Financial Technology Consulting Co., Ltd. [(2)]	Interest in controlled corporations	1,160,994,737	Long positions	53.71%
Ping An [(2)]	Beneficial owner	1,160,994,737	Long positions	53.71%
Glorious Peace [(2)]	Interest in controlled corporations	1,160,994,737	Long positions	53.71%
Morgan Stanley	Interest in controlled corporations	126,404,850	Long positions	5.84%
		113,610,502	Short positions	5.25%

Notes:

(1) The calculation is based on the total number of Shares in issue of 2,161,443,720 of the Company as of 30 June 2026.

(2) As of 30 June 2026, Glorious Peace directly held a total of 1,160,994,737 Shares. Glorious Peace was wholly-owned by An Ke Technology Company Limited, which in turn was wholly-owned by Shenzhen Ping An Financial Technology Consulting Co., Ltd., which in turn was wholly-owned by Ping An. As such, each of Ping An, An Ke Technology Company Limited and Shenzhen Ping An Financial Technology Consulting Co., Ltd. was deemed to be interested in the Shares held by Glorious Peace.

(3) Pursuant to section 336 of the SFO, the Shareholders are required to file forms of disclosure of interests when certain criteria are fulfilled and the full details of the requirements are available on the Stock Exchange's official website. When a Shareholder's shareholding in the Company changes, it is not necessary to notify the Company and the Stock Exchange unless certain criteria are fulfilled. Therefore, substantial Shareholders' latest shareholdings in the Company may be different to the shareholdings filed with the Company and the Stock Exchange. The Company may not have sufficient information on the breakdown of the relevant interests and cannot verify the accuracy of information in the forms of disclosure of interest.

Save as disclosed above, as of 30 June 2026, the Directors were not aware of any person (other than the Directors or chief executives of the Company) who had interests or short positions in the Shares or underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or were recorded in the register required to be kept by the Company under section 336 of the SFO, or who was, directly or indirectly, interested in 5% or more of the Shares of the Company.

Employee Incentive Scheme

The Employee Incentive Scheme was approved by the Board on 26 December 2014 and amended by the Board from time to time. The purpose of the Employee Incentive Scheme is to attract and retain talents, and promote the long-term sustainable development of the Company and related entities, so as to realize the maximization of value for Shareholders, and achieve mutual benefits of the Shareholders, the Company and the employees.

The EIS Shares had been issued, which were directly held by Le An Xin. Given the EIS Shares had already been issued, there will not be any dilution effect to the proportion of shareholding upon the exercise of the options granted under the EIS. In addition, the grant of the EIS Options by the Company or transfer upon vesting of the EIS Options of any of the EIS Shares pursuant to the Employee Incentive Scheme by any trustee or trust holding entities to a connected person of the Company should not be subject to the requirements of Chapter 14A of the Listing Rules. The aggregate number of EIS Shares which may be granted by the Company in accordance with the EIS is 70,000,000 Shares (subject to share subdivision on the Listing Date). As of 1 January 2026, the number of EIS Shares available for grant was 27,282,746 Shares, representing 1.26% of the issued Shares as at the date of this report. As of 30 June 2026, the number of EIS Shares remaining available for grant was 27,358,821 Shares, representing 1.27% of the issued Shares as at the date of this report. As of 30 June 2026, the aggregate number of Shares underlying the outstanding EIS Options granted by the Company under the EIS was 7,395,187 Shares (subject to share subdivision on the Listing Date), representing 0.34% of the issued Shares as at the date of this report. All such Shares underlying the EIS Options have been issued.

The following table shows details of the options granted under the EIS for the six months ended 30 June 2026:

Name	Position	Date of grant[1]	Number of grants (Shares)	Vesting period[2]	Exercise price (HK$/share)	Outstanding as of 1 January 2026 (Shares)	Exercised during the Reporting Period[3] (Shares)	Cancelled/ Lapsed during the Reporting Period (Shares)	Outstanding as of 30 June 2026 (Shares)
Mr. Mingke He[6]	Executive Director and chief executive officer	30 December 2025	1,162,433	7 October 2026 to 7 October 2028	-	1,162,433	-	-	1,162,433
Ms. Luoqi Zang (Resigned)[7]	Executive Director, executive vice president and chief financial officer	15 March 2022	250,000	15 March 2023 to 15 March 2026	-	188,450	-	-	188,450
Five highest paid individuals in aggregate		26 October 2021	300,000	26 October 2022 to 26 October 2025	-	151,140	-	-	151,140
		23 October 2022	100,000	23 October 2023 to 23 October 2026	-	75,380	-	-	75,380
		1 December 2023	300,000	1 December 2024 to 1 December 2027	-	150,000	63,750	11,250	75,000
		30 December 2025	1,162,433	7 October 2026 to 7 October 2028	-	1,162,433	-	-	1,162,433
Other grantees		31 December 2014	4,917,500	31 December 2015 to 31 December 2018	0.63	-	-	-	-
		31 March 2015	280,000	31 March 2016 to 31 March 2019	0.63	-	-	-	-
		30 June 2015	148,000	30 June 2016 to 30 June 2019	0.63	-	-	-	-
		1 October 2015	11,534,500	1 October 2016 to 1 October 2019	0.91	-	-	-	-

Name	Position	Date of grant[1]	Number of grants (Shares)	Vesting period[2]	Exercise price (HK$/share)	Outstanding as of 1 January 2026 (Shares)	Exercised during the Reporting Period[3] (Shares)	Cancelled/ Lapsed during the Reporting Period (Shares)	Outstanding as of 30 June 2026 (Shares)
		25 February 2016	3,923,000	25 February 2017 to 25 February 2020	5.95	-	-	-	-
		31 March 2017	16,475,800	31 March 2018 to 31 March 2021	26.47	499,214	-	-	499,214
		30 November 2017	14,287,098	30 November 2018 to 30 November 2021	37.84	962,276	-	-	962,276
		31 December 2017	840,000	31 December 2018 to 31 December 2021	37.84	-	-	-	-
		28 February 2019	3,867,694	28 February 2020 to 28 February 2023	0-36.21	57,894	-	-	57,894
		31 May 2019	188,335	31 May 2020 to 31 May 2023	-	38	-	-	38
		31 August 2019	110,713	31 August 2020 to 31 August 2023	-	-	-	-	-
		8 September 2019	100,000	8 September 2020 to 8 September 2023	-	-	-	-	-
		30 November 2019	25,575	30 November 2020 to 21 October 2023	-	-	-	-	-
		21 October 2020	1,952,100	21 October 2021 to 21 October 2024	-	225,852	-	-	225,852
		31 December 2020	166,600	31 December 2021 to 31 December 2024	-	2,808	-	-	2,808
		11 January 2021	300,000	21 October 2021 to 21 October 2024	-	76,140	-	-	76,140
		31 May 2021	260,000	31 May 2022 to 31 May 2025	-	130,000	-	-	130,000
		24 August 2021	3,284,700	24 August 2022 to 24 August 2025	-	165,131	-	-	165,131
		26 October 2021	248,600	26 October 2022 to 26 October 2025	-	54	-	-	54
		29 January 2022	3,229,200	29 January 2023 to 29 January 2026	-	915,138	-	-	915,138

Name	Position	Date of grant[1]	Number of grants (Shares)	Vesting period[2]	Exercise price (HK$/share)	Outstanding as of 1 January 2026 (Shares)	Exercised during the Reporting Period[3] (Shares)	Cancelled/ Lapsed during the Reporting Period (Shares)	Outstanding as of 30 June 2026 (Shares)
		15 March 2022	250,000	15 March 2023 to 15 March 2026	-	188,450	-	-	188,450
		20 May 2022	230,000	20 May 2023 to 20 May 2026	-	7,614	-	-	7,614
		26 July 2022	25,000	26 July 2023 to 26 July 2026	-	-	-	-	-
		23 October 2022	475,000	23 December 2023 to 23 December 2026	-	226,805	-	-	226,805
		19 December 2022	5,512,000	19 December 2023 to 19 December 2026	-	2,376,645	-	59,825	2,316,820
		23 November 2024	162,000	23 November 2025 to 23 November 2028	-	162,000	-	5,000	157,000
Total[4]			**74,655,848[5]**			**7,535,012**	**63,750**	**76,075**	**7,395,187**

Notes:

1. The performance of the EIS Options granted during the Reporting Period depended on the degree of satisfaction of specific performance, including fulfillment of the key performance indicators by the Group as a whole and the grantees;

2. The EIS Options may be exercised once vested, subject to a period of 10 years commencing from the date of grant;

3. The closing price on the date immediately before the date on which the EIS Options were exercised was HK$11.29/share;

4. For the avoidance of double counting, total represents the sum of the options of the five highest paid individuals (including Mr. Mingke He) and other grantees (including Ms. Luoqi Zang);

5. The number of shares granted was the number of shares originally granted, including the number of shares canceled/lapsed and re-granted;

6. Depending on the performance of the Group as a whole and individual performance, Mr. Mingke He was entitled to a maximum of 1,278,676 Shares pursuant to the Employee Incentive Scheme;

7. Ms. Luoqi Zang resigned as an executive Director, the executive vice president, the chief financial officer, the secretary to the Board, the company secretary and the authorized representative of the Company on 16 June 2026 due to personal work arrangement.

Purchase, Sale or Redemption of the Company's Listed Securities

For the six months ended 30 June 2026, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sales of treasury shares within the meaning of the Listing Rules). As of 30 June 2026, the Company did not hold any of these treasury shares.

Changes of Directors and Chief Executives and Their Information

During the Reporting Period and up to the date of this interim results announcement, changes of Directors and chief executives are set out as follows:

1. Ms. Qin Xu was appointed as the chief financial officer, the secretary to the Board, the joint company secretary and the authorized representative of the Company on 16 June 2026.

2. Mr. Roy, Sing Yuen Chan was appointed as the joint company secretary of the Company on 16 June 2026.

3. Ms. Luoqi Zang resigned as an executive Director, the executive vice president, the chief financial officer, the secretary to the Board, the company secretary and the authorized representative of the Company on 16 June 2026 due to personal work arrangement.

4. Mr. Cheng Liu resigned as the secretary to the Board, the company secretary and the authorized representative of the Company on 24 March 2026 due to personal work arrangement.

Pursuant to the disclosure requirement under Rule 13.51B(1) of the Listing Rules, the changes in personal information of the Directors are as follows:

1. Ms. Xin Fu, a non-executive Director, ceased to be a director of Lufax Holding since February 2026 and a non-executive director of OneConnect since July 2026.

2. Ms. Fangfang Cai, a non-executive Director, served as a non-executive director of Lufax Holding from February 2026 to July 2026, and ceased to be an executive director and a member of the related party transaction control and consumer rights protection committee under the board of Ping An/Ping An Insurance (Group) since May 2026.

Audit and Risk Management Committee

The Company has established an Audit and Risk Management Committee in compliance with the Corporate Governance Code. The primary duties of the Audit and Risk Management Committee are to review and supervise the financial reporting process and internal control system of the Group, review the financial information of the Group and consider issues relating to the external auditors and their appointment.

The Audit and Risk Management Committee comprises two independent non-executive Directors, namely, Mr. Yunwei Tang and Mr. Tianyong Guo and one non-executive Director, namely, Ms. Fangfang Cai. Mr. Yunwei Tang, being the chairman of the Audit and Risk Management Committee, is appropriately qualified as required.

The Audit and Risk Management Committee has reviewed the unaudited interim financial accounts of the Group for the six months ended 30 June 2026. The Audit and Risk Management Committee has also discussed with management of the Company the accounting policies and practices and internal controls adopted by the Company. Based on the above review and discussion with management, the Audit and Risk Management Committee is satisfied that the unaudited interim financial information of the Group has been prepared in accordance with the applicable accounting standards.

Compliance with the Code of Conduct Regarding Directors' Securities Transactions

The Company has adopted the Model Code as the code of conduct regarding Directors' dealings in the securities of the Company. Having made specific enquiry to all the Directors of the Company, all the Directors of the Company confirmed that they have complied with the required standards set out in the Model Code for the six months ended 30 June 2026.

The Board has also established written guidelines to regulate all dealings by informed persons who are likely to be in possession of inside information in respect of the Company's securities and unpublished information as referred to in code provision C.1.3 of the Corporate Governance Code.

Compliance with the Corporate Governance Code

According to code provision B.3.5 of the Corporate Governance Code, issuers should appoint at least one director of a different gender to the nomination committee. During the Reporting Period, the members of the Nomination and Remuneration Committee under the Board of the Company are all of the same gender. After considering: (1) the Board currently has two female Directors, representing 25% of the total Board members, and the overall composition of the Board already demonstrates the Company's commitment to promoting gender diversity; (2) the Company has adopted and implemented the Board diversity policy, recognizes and embraces the benefits of having a diverse Board, and sees diversity at the Board level as an essential element in maintaining a competitive advantage; (3) the members of the Nomination and Remuneration Committee are currently composed of Directors with diverse backgrounds and perspectives, maintaining an appropriate balance in terms of independence, expertise and management experience, and are capable of providing effective advice in reviewing the Board structure and promoting the Board diversity; (4) the nominations of Directors of the Company are conducted through open, transparent and compliant procedures, the Board is therefore of the view that the current composition of the Nomination and Remuneration Committee does not have a material impact on its performance of relevant duties or on the promotion of the Board diversity.

On 19 August 2026, Ms. Yanjun Fan is appointed as a non-executive Director and a member of the Nomination and Remuneration Committee of the Company. Since that date, the Company has complied with the above requirements of code provision B.3.5 of the Corporate Governance Code.

The Directors confirmed that except for the above matters, the Company had complied with all the applicable code provisions as set out in the Corporate Governance Code for the six months ended 30 June 2026.

Use of Proceeds

Use of Net Proceeds from the Listing

The Shares of the Company were listed on the Main Board of the Stock Exchange on the Listing Date with net proceeds received by the Company from the global offering in the amount of approximately HK$8,564.0 million after deducting underwriting commissions and all related expenses. The proceeds from the Listing were used and are proposed to be used according to the intentions previously disclosed by the Company.

Use of Net Proceeds from the Placing

References are made to the announcements of the Company dated 30 September 2020 and 9 October 2020 (the "Announcements"), and for the purposes of seizing market opportunities, solidifying the Company's leading position in the industry and laying a solid foundation for business expansion, on 30 September 2020, the Company entered into a placing agreement with the placing agents in relation to the placing of an aggregate of 80,000,000 new Shares with the aggregate nominal value of USD400, at a placing price of HK$98.20 per placing share on the terms and conditions set out in the placing agreement. The market price of the placing shares was HK$99.25 on the date of the placing agreement.

On 9 October 2020, the Company completed the placing of 80,000,000 ordinary shares to no less than six placees who are Independent Third Parties of the Company at a price of HK$98.20 per placing share with net proceeds received by the Company from the placing in the amount of approximately HK$7,828.0 million after deducting the commission, incentive fee and expense, representing a net issue price of approximately HK$97.85 per placing share. The proceeds from the placing are proposed to be used according to the intentions previously disclosed by the Company.

Timetable for the Use of Proceeds

The table below sets out the Group's intended timetable for the use of proceeds as at 30 June 2026:

Intended use of net proceeds	Allocation of net proceeds	Amount of net proceeds utilized as of 30 June 2026	Balance of net proceeds unutilized as of 30 June 2026	Intended timetable for use of the unutilized net proceeds [1]
		(HK$ in million)		
Funding our potential investments, acquisitions of domestic companies and the strategic alliances with domestic companies as well as our overseas expansion plan	544.9	–	544.9	Before 31 December 2028

Note:

1. The expected timetable for the use of the unutilized net proceeds is made based on the best estimation of the Company taking into account, among others, the prevailing and future market conditions and business development and need, and is therefore subject to change.

Independent Review Report

To the board of directors of Ping An Healthcare and Technology Company Limited
(incorporated in the Cayman Islands with limited liability)

Introduction

We have reviewed the interim financial information set out on pages 35 to 56, which comprises the condensed consolidated statement of financial position of Ping An Healthcare and Technology Company Limited (the "Company") and its subsidiaries (the "Group") as at 30 June 2026 and the related condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting" ("IAS 34") as issued by the International Accounting Standards Board ("IASB"). The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Scope of Review

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* as issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young
Certified Public Accountants

Hong Kong
18 August 2026

Interim Condensed Consolidated Statements of Profit or Loss

For the six months ended 30 June 2026

	Notes	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Revenue	5	**2,483,833**	2,502,193
Cost of sales		**(1,527,163)**	(1,662,484)
Gross profit		**956,670**	839,709
Selling and marketing expenses		**(386,069)**	(381,020)
Administrative expenses		**(405,512)**	(371,947)
Impairment losses on financial and contract related assets		**(1,011)**	(30,190)
Other income		**13,125**	16,468
Other gains, net		**38,882**	1,848
Finance income, net		**44,612**	60,033
Share of profits and losses of associates		**(10,044)**	1,359
PROFIT BEFORE TAX		**250,653**	136,260
Income tax expense	7	**(30,880)**	(1,352)
PROFIT FOR THE PERIOD		**219,773**	134,908
Attributable to:			
– Owners of the parent		**219,332**	134,164
– Non-controlling interests		**441**	744
		219,773	134,908
EARNINGS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY			
– Basic (RMB yuan)	8	**0.10**	0.07
– Diluted (RMB yuan)	8	**0.10**	0.07

Interim Condensed Consolidated Statement of Comprehensive Income

For the six months ended 30 June 2026

	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Profit for the period	**219,773**	134,908
Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**(56,342)**	(28,764)
OTHER COMPREHENSIVE LOSS FOR THE PERIOD	**(56,342)**	(28,764)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**163,431**	106,144
Attributable to:		
– Owners of the parent	**162,990**	105,400
– Non-controlling interests	**441**	744
	163,431	106,144

Interim Condensed Consolidated Statement of Financial Position

As at 30 June 2026

	Notes	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
NON-CURRENT ASSETS			
Goodwill	9	**1,677,692**	1,677,692
Right-of-use assets		**28,332**	38,623
Property, plant and equipment	10	**76,637**	85,874
Other intangible assets		**4,940**	9,582
Investments in associates and joint ventures		**63,098**	72,829
Financial assets at fair value through profit or loss ("FVTPL")		**1,865,161**	1,888,112
Restricted cash	12	**105,000**	300,000
Term deposits	12	**466,976**	469,937
Total non-current assets		**4,287,836**	4,542,649
CURRENT ASSETS			
Inventories		**78,028**	63,325
Trade receivables	11	**923,101**	1,032,978
Contract related assets		**153,012**	179,805
Prepayments and other receivables		**432,288**	440,048
Financial assets at FVTPL		**1,790,277**	2,876,559
Restricted cash	12	**870,805**	676,371
Term deposits	12	**121,772**	1,698,696
Cash and cash equivalents	12	**4,421,438**	1,720,072
Total current assets		**8,790,721**	8,687,854

Interim Condensed Consolidated Statement of Financial Position

As at 30 June 2026

	Notes	**30 June 2026** **RMB'000** **(Unaudited)**	31 December 2025 RMB'000 (Audited)
CURRENT LIABILITIES			
Trade and other payables	13	**2,034,699**	2,115,122
Contract liabilities		**780,902**	1,073,513
Lease liabilities		**21,540**	25,243
Tax payable		**30,382**	–
Provisions		**5,400**	–
Total current liabilities		**2,872,923**	3,213,878
NET CURRENT ASSETS		**5,917,798**	5,473,976
TOTAL ASSETS LESS CURRENT LIABILITIES		**10,205,634**	10,016,625
NON-CURRENT LIABILITIES			
Lease liabilities		**7,520**	14,547
Trade and other payables	13	**10,546**	48
Contract liabilities		**115,062**	96,915
Total non-current liabilities		**133,128**	111,510
Net assets		**10,072,506**	9,905,115
EQUITY			
Equity attributable to owners of the Company			
Share capital	15	**72**	72
Treasury shares		**(1)**	(1)
Reserves		**16,616,413**	16,669,585
Accumulated losses		**(6,533,899)**	(6,753,231)
		10,082,585	9,916,425
Non-controlling interests		**(10,079)**	(11,310)
Total equity		**10,072,506**	9,905,115

Michael Guo
(Director)

He Mingke
(Director)

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2026

	Attributable to owners of the Company						
	Share capital RMB'000	Treasury shares RMB'000	Reserves RMB'000	Accumulated losses RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
As at 1 January 2026 (audited)	**72**	**(1)**	**16,669,585**	**(6,753,231)**	**9,916,425**	**(11,310)**	**9,905,115**
Profit for the period	**-**	**-**	**-**	**219,332**	**219,332**	**441**	**219,773**
Other comprehensive loss for the period	**-**	**-**	**(56,342)**	**-**	**(56,342)**	**-**	**(56,342)**
Total comprehensive income for the period	**-**	**-**	**(56,342)**	**219,332**	**162,990**	**441**	**163,431**
Share of other reserves of an associate	**-**	**-**	**314**	**-**	**314**	**-**	**314**
Deemed contribution from a minority shareholder	**-**	**-**	**790**	**-**	**790**	**790**	**1,580**
Share-based payments	**-**	**-**	**4,747**	**-**	**4,747**	**-**	**4,747**
Long-term service plan*	**-**	**-**	**(2,681)**	**-**	**(2,681)**	**-**	**(2,681)**
As at 30 June 2026 (unaudited)	**72**	**(1)**	**16,616,413**	**(6,533,899)**	**10,082,585**	**(10,079)**	**10,072,506**

* Certain core personnels were transferred to the Group from Ping An Insurance (Group) Company of China, Ltd. ("Ping An") and its subsidiaries in 2025. They participated in the long-term service plan implemented by Ping An during previous years, and are entitled to apply for awarded shares upon satisfaction of certain conditions. The Group was recharged by Ping An and its subsidiaries in relation to the long-term service plan with a consideration of RMB2,863,000 during the period ended 30 June 2026. In addition, cost of employee services for the Group under the long-term service plan was RMB182,000 during the period ended 30 June 2026.

	Attributable to owners of the Company						
	Share capital RMB'000	Treasury shares RMB'000	Reserves RMB'000	Accumulated losses RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
As at 1 January 2025 (audited)	35	(1)	10,722,077	(7,132,742)	3,589,369	(9,750)	3,579,619
Profit for the period	–	–	–	134,164	134,164	744	134,908
Other comprehensive loss for the period	–	–	(28,764)	–	(28,764)	–	(28,764)
Total comprehensive income for the period	–	–	(28,764)	134,164	105,400	744	106,144
Election of scrip dividend	37	–	6,003,704	–	6,003,741	–	6,003,741
Share-based payments	–	–	5,325	–	5,325	–	5,325
Exercise of share options	–	–	370	–	370	–	370
As at 30 June 2025 (unaudited)	72	(1)	16,702,712	(6,998,578)	9,704,205	(9,006)	9,695,199

Interim Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2026

	Notes	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Cash flows from operating activities			
Cash generated from operations		**26,270**	64,709
Income tax paid		**(878)**	(1,152)
Net cash generated from operating activities		**25,392**	63,557
Cash flows from investing activities			
Proceeds from disposal of property, plant and equipment and intangible assets		**154**	17
Payments for property, plant and equipment and intangible assets		**(6,993)**	(3,582)
Payments for financial assets at fair value through profit or loss		**(1,792,158)**	(5,271,848)
Proceeds from sales of financial assets at fair value through profit or loss		**2,894,591**	9,576,335
Payments for term deposits with initial term of over three months		**(56,099)**	(567,112)
Interest received from term deposits with initial term of over three months		**40,122**	52,559
Proceeds from term deposits with initial term of over three months		**1,619,590**	884,956
Net cash generated from investing activities		**2,699,207**	4,671,325
Cash flows from financing activities			
Payments for lease liabilities		**(21,245)**	(18,044)
Dividend paid		**–**	(3,906,599)
Proceeds from exercise of share options		**–**	370
Net cash used in financing activities		**(21,245)**	(3,924,273)
Net increase in cash and cash equivalents		**2,703,354**	810,609
Cash and cash equivalents at the beginning of the period		**1,720,072**	2,044,653
Effects of exchange rate changes on cash and cash equivalents		**(1,988)**	(2,250)
Cash and cash equivalents at the end of the period		**4,421,438**	2,853,012
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
Cash and bank balance		**481,336**	773,945
Short-term bank deposits with initial term within three months		**3,873,402**	2,007,155
Other cash equivalents		**66,700**	71,912
Cash and cash equivalents as stated in the statement of financial position and cash flows		**4,421,438**	2,853,012

1 GENERAL INFORMATION

Ping An Healthcare and Technology Company Limited (the "Company") was incorporated in the Cayman Islands on 12 November 2014 as an exempted company with limited liability under the Companies Law (Cap. 22, Law 3 of 1961 as consolidated and revised) of the Cayman Islands. The address of the Company's registered office is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The Company is an investment holding company. The Company and its subsidiaries are principally engaged in offering medical and health services through the Group's mobile platform in the People's Republic of China (the "PRC").

Glorious Peace Limited ("Glorious Peace") is the controlling shareholder of the Company, holding 53.71% of the shareholding interest in the Company as at 30 June 2026. In the opinion of the directors, Ping An is the ultimate parent company of the Company.

2 BASIS OF PREPARATION

This interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025.

3 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2025, except for the adoption of the following amended IFRS Accounting Standards for the first time for the current period's financial information.

Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity
Annual Improvements to IFRS Accounting Standards – Volume 11	Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7

3 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

The nature and impact of the amended IFRS Accounting Standard are described below:

(a) Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments clarify that a financial asset is derecognised when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognised on the settlement date. The amendments introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any impact on the interim condensed consolidated financial information. The Group will provide additional disclosures for its equity investments designated at fair value through other comprehensive income in the Group's consolidated financial statements for the year ending 31 December 2026.

(b) Amendments to IFRS 9 and IFRS 7 Contracts Referencing Nature-dependent Electricity clarify the application of the "own-use" requirements for in-scope contracts and amend the designation requirements for a hedged item in a cash flow hedging relationship for in-scope contracts. The amendments also include additional disclosures that enable users of financial statements to understand the effects these contracts have on an entity's financial performance and future cash flows. As the Group did not have any contracts that are in the scope of the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.

(c) Annual Improvements to IFRS Accounting Standards – Volume 11 set out narrow scope amendments to IFRS 1, IFRS 7 (and the accompanying Guidance on implementing IFRS 7), IFRS 9, IFRS 10 and IAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding IFRS Accounting Standards. The amendments did not have any impact on the interim condensed consolidated financial information.

4 OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their services and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

Geographical information

Since substantially all of the Group's revenue and operating profit were generated from the Chinese mainland and most of the Group's identifiable operating assets were located in the Chinese mainland, no geographical segment information in accordance with IFRS 8 Operating Segments is presented.

Information about a major customer

Revenue of approximately RMB1,051,499,000 (six months ended 30 June 2025: RMB702,553,000) was derived from the sale of goods and services provided to a single customer, including sales to a group of entities which are known to be under common control with that customer.

5 REVENUE

An analysis of revenue is as follows:

	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Revenue from contracts with customers	**2,483,833**	2,502,193

Revenue from contracts with customers

(a) Disaggregated revenue information

	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Commercial insurance enablement	**1,584,427**	1,584,313
Corporate health management	**713,842**	432,361
Others	**185,564**	485,519
Total	**2,483,833**	2,502,193

Timing of revenue recognition

	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
At a point in time	**2,277,228**	2,278,517
Overtime	**206,605**	223,676
Total	**2,483,833**	2,502,193

6 PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	2026 **RMB'000** **(Unaudited)**	2025 RMB'000 (Unaudited)
Cost for service fee paid to venders	**843,866**	714,808
Cost of merchandise	**592,792**	824,034
Impairment provision for investment in associates	**–**	40,050
Impairment provision for inventory	**3,256**	325
Impairment losses on financial and contract related assets	**1,011**	30,190
Fair value gains on financial assets at fair value through profit or loss	**(45,462)**	(63,643)
Investment income on short-term investments placed with banks	**(3,454)**	(1,371)
Interest income	**(45,559)**	(61,810)
Depreciation of right-of-use assets	**18,230**	18,006
Depreciation of property, plant and equipment	**14,880**	12,757
Amortization of other intangible assets	**4,678**	6,821
Remuneration of the auditors	**2,534**	2,104
Staff cost (including directors' remuneration)*	**406,950**	416,572
Net foreign exchange losses	**2,280**	24,516

* The amount of the staff cost is included in "Cost of sales", "Selling and marketing expenses" and "Administrative expenses" in the consolidated statements of profit or loss.

7 INCOME TAX EXPENSE

The income tax expense of the Group for the period ended 30 June 2026 is analyzed as follows:

	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Current income tax – Chinese Mainland	**30,880**	1,352

(a) Cayman Islands Income Tax
The Company is incorporated under the laws of the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands and accordingly is not subject to Cayman Islands income tax.

(b) Hong Kong Income Tax
The subsidiaries incorporated in Hong Kong are subject to Hong Kong profits tax at the rate of 16.5% (2025: 16.5%) on the estimated assessable profits arising in Hong Kong during the period. No Hong Kong profits tax was provided for as there was no estimated assessable profit that was subject to Hong Kong profits tax during the six months ended 30 June 2026 and 2025.

(c) PRC Corporate Income Tax ("CIT")
The income tax provision of the Group in respect of its operations in PRC was calculated at the tax rate of 25% on the assessable profits, based on the existing legislation, interpretations and practices in respect thereof. According to the relevant tax circulars issued by the PRC tax authorities, some subsidiaries of the Group are entitled to certain tax concessions because they are small and micro enterprises.

(d) PRC withholding Tax ("WHT")
According to the New Corporate Income Tax Law ("New CIT Law"), distribution of profits earned by PRC companies since 1 January 2008 to foreign investors is subject to withholding tax of 5% or 10%, depending on the country of incorporation of the foreign investor, upon the distribution of profits to overseas-incorporated immediate holding companies. WHT of the Group was levied on the investment income earned by the Company and overseas subsidiaries.

The Group does not have any plan to require its PRC subsidiaries to distribute their retained earnings and intends to retain them to operate and expand its business in the PRC. Accordingly, no deferred income tax liability on WHT was accrued as at 30 June 2026 (unaudited) (as at 31 December 2025 (audited): nil).

8 EARNINGS PER SHARE

(a) Basic earnings per share for the six months ended 30 June 2026 and 2025 are calculated by dividing the earnings attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the period.

The calculation of earnings per share is based on the following:

	2026 (Unaudited)	2025 (Unaudited)
Profit attributable to ordinary equity holders of the parent for the period (RMB'000)	**219,332**	134,164
Weighted average number of ordinary shares outstanding during the period ('000)	**2,126,658**	1,988,353
Basic earnings per share attributable to ordinary equity holders of the parent (RMB yuan)	**0.10**	0.07

(b) Diluted earnings per share are calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

For the six months ended 30 June 2026 and 2025, the Group has share options as potential dilutive ordinary shares which was included in the calculation of diluted earnings per share.

	2026 (Unaudited)	2025 (Unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent for the period (RMB'000)	**219,332**	134,164
Weighted average number of ordinary shares		
Weighted average number of ordinary shares outstanding during the period used in the basic earnings per share calculation ('000)	**2,126,658**	1,988,353
Adjustments for:		
Assumed exercise of share options ('000)	**5,335**	3,678
Weighted average number of ordinary shares for diluted earnings per share ('000)	**2,131,993**	1,992,031
Diluted earnings per share attributable to ordinary equity holders of the parent (RMB yuan)	**0.10**	0.07

9 GOODWILL

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Medical services related CGU	**1,289,682**	1,289,682
Health services related CGU	**379,246**	379,246
Others	**8,764**	8,764
	1,677,692	1,677,692
Impairment (Note a)	**–**	–
Net carrying amount	**1,677,692**	1,677,692

Notes:

(a) As at 30 June 2026, management reviewed the cash flow projections which was based on business plan and used to prepare goodwill impairment testing as at 31 December 2025. Management found no significant change on the business plan and did not identify any impairment indicators on goodwill.

10 PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2026, the Group acquired assets at a cost of RMB6,168,000 (30 June 2025: RMB3,211,000). Assets with a net book value of RMB525,000 were disposed of by the Group during the six months ended 30 June 2026 (30 June 2025: RMB18,000) resulting in a net loss on disposal of RMB371,000 (30 June 2025: Nil).

During the six months ended 30 June 2026, no impairment loss (30 June 2025: Nil) was recognised.

11 TRADE RECEIVABLES

An ageing analysis of trade receivables as at the end of the reporting period, based on the recognition and net of loss allowance, is as follows:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Up to 3 months	**501,676**	774,148
3 to 6 months	**266,823**	94,266
6 months to 1 year	**83,708**	97,304
1 to 2 years	**62,981**	48,072
More than 2 years	**7,913**	19,188
Total	**923,101**	1,032,978

12 CASH AND CASH EQUIVALENTS, RESTRICTED CASH AND TERM DEPOSITS

(a) Cash and cash equivalents

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Cash and bank balance	**481,336**	488,667
Short-term bank deposits with initial term within three months	**3,873,402**	1,136,288
Other cash equivalents	**66,700**	95,117
Total	**4,421,438**	1,720,072

Cash and cash equivalents are denominated in the following currencies:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
USD	**32,658**	12,579
HKD	**6,461**	48,748
RMB	**4,382,319**	1,658,745
Total	**4,421,438**	1,720,072

12 CASH AND CASH EQUIVALENTS, RESTRICTED CASH AND TERM DEPOSITS (Continued)

(b) Restricted cash

As at 30 June 2026, restricted deposits held at banks amounted to RMB975,805,369 (as at 31 December 2025: RMB976,371,000), of which RMB970,755,369 (as at 31 December 2025: RMB970,749,000) is legally frozen due to litigations.

In March 2025, term deposits in the amount of approximately RMB941,000,000 with initial term over one year were legally frozen due to an ongoing dispute. The Group won the first instance, and is awaiting the judgment of the second instance. The freeze is merely a routine court preservation procedure and does not represent any prejudgment regarding the outcome of the case.

(c) Term deposits

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Current assets		
Term deposits with initial term of over three months that will mature within one year	**121,948**	1,699,020
Impairment	**(176)**	(324)
Total	**121,772**	1,698,696
Non-current assets		
Term deposits with initial term of over three months that will mature over one year	**467,184**	470,301
Impairment	**(208)**	(364)
Total	**466,976**	469,937

Term deposits are denominated in the following currencies:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
RMB	**533,941**	2,125,953
HKD	**55,191**	18,064
USD	**–**	25,304
Total	**589,132**	2,169,321

The weighted average effective interest rate of the term deposits of the Group as at 30 June 2026 is 1.70% (as at 31 December 2025: 2.33%).

13 TRADE AND OTHER PAYABLES

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Current liabilities		
Trade payables (Note a)	**680,788**	704,244
Wages payables	**492,188**	573,707
Accruals	**469,001**	442,042
Other payables (Note b)	**243,058**	215,948
Other tax payable	**82,175**	107,118
Amounts due to related parties	**64,013**	68,588
Withholding tax payable	**3,476**	3,475
Total	**2,034,699**	2,115,122
Non-current liabilities		
Amounts due to related parties	**10,546**	48

Notes:

(a) Aging analysis of trade payables based on the accrual date is as follows:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Up to 3 months	**519,666**	582,428
3 to 6 months	**50,625**	6,391
6 months to 1 year	**44,660**	35,416
1 to 2 years	**13,101**	69,893
More than 2 years	**52,736**	10,116
Total	**680,788**	704,244

The trade payables are non-interest-bearing and are normally settled on terms ranging from 30 to 60 days.

(b) Other payables are non-interest-bearing and are normally settled on terms ranging from 30 to 60 days.

14 DIVIDENDS

No dividends have been declared (six months ended 30 June 2025: Nil) by the Company during the six months ended 30 June 2026.

15 SHARE CAPITAL

	Number of shares	USD
Authorised		
Ordinary shares of USD0.000005 each at 1 January 2026 (audited) and 30 June 2026 (unaudited)	10,000,000,000	50,000

	Number of shares	USD	Equivalent to RMB yuan
Issued			
Ordinary shares of USD0.000005 each at 1 January 2026 (audited) and 30 June 2026 (unaudited)	2,161,443,720	10,807	72,448

16 RELATED PARTY TRANSACTIONS

Save as those disclosed in the other notes, the following significant transactions were carried out between the Group and its related parties. In the opinion of the directors of the Company, the related party transactions were carried out in the normal course of business and at terms negotiated between the Group and the respective related parties. The Group's pricing policies of the transactions with related parties are determined on the basis of mutual negotiations between the relevant parties.

(a) Names and relationships with related parties

Name of related parties	Relationship with the Company
Glorious Peace	The shareholder that controls the Group
Ping An	Ultimate parent company of Glorious Peace
Ping An Life Insurance Company of China, Ltd. ("Ping An Life Insurance")	Controlled by Ping An
Ping An Property & Casualty Insurance Company of China, Ltd. ("Ping An Property & Casualty Insurance")	Controlled by Ping An
Ping An Bank Co., Ltd. ("Ping An Bank")	Controlled by Ping An
Ping An Health Insurance Company Ltd. ("Ping An Health Insurance")	Controlled by Ping An
Ping An Annuity Insurance Company, Ltd. ("Ping An Annuity")	Controlled by Ping An
Shenzhen Ping An Financial Technology Consulting Co., Ltd. ("Ping An Fintech")	Controlled by Ping An
Ping An Trust Co., Ltd. ("Ping An Trust"),	Controlled by Ping An
Ping An International Financial Leasing Company Limited ("Ping An Financial Leasing")	Controlled by Ping An
Ping An Asset Management Co., Ltd ("Ping An Asset Management")	Controlled by Ping An
China Ping An Insurance Overseas (Holdings) Limited ("Ping An Overseas Holdings")	Controlled by Ping An
Yingjian Enterprise Management Consulting (Shanghai) Co., Ltd. ("Yingjian Enterprise Management Consulting")	Shareholder of the subsidiary of the Group

16 RELATED PARTY TRANSACTIONS (Continued)

(b) Significant transactions with related parties

	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Trademark licensing		
Ping An	**–**	–
Provision of products and services		
Ping An Life Insurance and its subsidiaries	**450,742**	391,667
Ping An Property & Casualty Insurance and its subsidiaries	**429,009**	137,750
Ping An Health Insurance	**64,990**	67,750
Ping An Bank and its subsidiaries	**52,396**	57,057
Ping An Fintech and its subsidiaries	**35,329**	22,686
Ping An Annuity	**15,430**	21,483
Services purchasing		
Ping An Financial Leasing and its subsidiaries	**102,105**	72,239
Ping An Fintech and its subsidiaries	**92,613**	133,153
Ping An Bank and its subsidiaries	**57,917**	5,174
Ping An Health Insurance	**9,221**	62,485
Ping An Annuity	**6,093**	4,564
Ping An Life Insurance and its subsidiaries	**5,894**	2,544
Ping An	**4,238**	–
Ping An Property & Casualty Insurance and its subsidiaries	**797**	8,496
Deposit interests		
Ping An Bank and its subsidiaries	**16,688**	10,520
Investment income		
Ping An Asset Management and its subsidiaries	**11,088**	629
Ping An Overseas Holdings and its subsidiaries	**3,820**	–
Ping An Bank and its subsidiaries	**3,520**	14,692
Ping An Trust and its subsidiaries	**597**	–
Property leasing expenses paid		
Ping An Life Insurance and its subsidiaries	**7,615**	6,432
Ping An Property & Casualty Insurance and its subsidiaries	**1,575**	278

16 RELATED PARTY TRANSACTIONS (Continued)

(c) Period/year end balances with related parties

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Cash and cash equivalents and term deposits		
Ping An Bank and its subsidiaries	**3,225,918**	454,245
Ping An Fintech and its subsidiaries	**46,412**	73,329
Restricted cash		
Ping An Bank and its subsidiaries	**34,755**	35,138
Financial assets at fair value through profit or loss		
Ping An Bank and its subsidiaries	**554,003**	681,190
Ping An Asset Management and its subsidiaries	**523,557**	1,344,733
Ping An Overseas Holdings and its subsidiaries	**259,364**	109,209
Ping An Trust and its subsidiaries	**30,623**	30,026
Trade receivables		
Ping An Life Insurance and its subsidiaries	**383,842**	410,215
Ping An Property & Casualty Insurance and its subsidiaries	**152,414**	224,660
Ping An Health Insurance	**63,965**	88,905
Ping An Fintech and its subsidiaries	**60,850**	48,869
Ping An Bank and its subsidiaries	**39,837**	63,140
Ping An Financial Leasing and its subsidiaries	**7,251**	13,045
Ping An Annuity	**3,571**	5,253
Prepayments and other receivables		
Deposits in security		
Ping An Fintech and its subsidiaries	**18,332**	21,982
Ping An Life Insurance and its subsidiaries	**3,142**	3,216
Amounts due from related parties		
Ping An Health Insurance	**7,660**	7,276
Ping An Fintech and its subsidiaries	**7,416**	9,394
Ping An Property & Casualty Insurance and its subsidiaries	**2,622**	2,470
Trade and other payables		
Ping An Fintech and its subsidiaries	**33,672**	25,521
Yingjian Enterprise Management Consulting	**10,500**	11,955
Ping An Property & Casualty Insurance and its subsidiaries	**10,232**	9,731
Ping An Life Insurance and its subsidiaries	**5,404**	3,249
Ping An	**2,511**	29
Ping An Health Insurance	**1,694**	1,758

16 RELATED PARTY TRANSACTIONS (Continued)

(c) Period/year end balances with related parties (Continued)

Apart from the interest receivables generated from term deposits and financial assets at fair value through profit or loss due from Ping An Bank calculated based on deposit interest rates, the other balances including other prepayments and other receivables, trade receivables and deposits due from related parties are unsecured, interest-free and repayable on demand.

On January 5, 2023, the Group entered into an agreement with minority shareholder Yingjian Enterprise Management Consulting to obtain a loan of RMB10,500,000 at an agreed interest rate of 4.75%. On February 10, 2026, a loan extension agreement was signed, extending the loan to February 10, 2029.

On February 10, 2026, the Group and Yingjian Enterprise Management Consulting signed an agreement to waive the interest on the RMB10,500,000 loan for historical years and to continue waiving future interest.

Apart from the loan mentioned above, the balances of trade and other payables due to related parties are unsecured, interest-free and repayable on demand.

17 FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, restricted cash, term deposits, trade receivables and financial assets included in prepayments and other receivables and financial liabilities included in trade and other payables approximate to their carrying amounts largely due to the short-term maturities of these instruments.

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The Group invests in financial assets at FVTPL, which represent wealth management products and structured deposits, and investment funds. The fair values are based on cash flows discounted using the expected yield rate.

The fair values of the non-current portion of term deposits have been calculated by discounting the future cash flows using the expected yield rate.

17 FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2026

	Fair value measurement using			
	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
	RMB'000	RMB'000	RMB'000	RMB'000
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Financial assets at fair value through profit or loss	–	3,655,438	–	3,655,438

As at 31 December 2025

	Fair value measurement using			
	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
	RMB'000	RMB'000	RMB'000	RMB'000
Financial assets at fair value through profit or loss	–	4,764,671	–	4,764,671

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (six months ended 30 June 2025: Nil).

The Group did not have any financial liabilities measured at fair value as at 30 June 2026 (as at 31 December 2025: Nil).

18 EVENTS AFTER THE REPORTING PERIOD

There were no material subsequent events need to be disclosed during the period from 30 June 2026 to the approval date of the interim consolidated financial information by the Board of Directors on 18 August 2026.

19 APPROVAL OF THE FINANCIAL INFORMATION

The interim condensed consolidated financial information was approved and authorized for issue by the Board of Directors on 18 August 2026.

Definitions

In this interim report, unless the context otherwise requires, the following expressions shall have the following meanings:

"Audit and Risk Management Committee"	Audit and Risk Management Committee under the Board
"Bank"/"Ping An Bank"	Ping An Bank Co., Ltd. (平安銀行股份有限公司), a company incorporated under the laws of the PRC on 22 December 1987 whose shares are listed on the Shenzhen Stock Exchange (SZSE: 000001), and a subsidiary of Ping An
"Board"	the board of directors of the Company
"Company" or "the Company"	Ping An Healthcare and Technology Company Limited (平安健康醫療科技有限公司), an exempted company incorporated in the Cayman Islands with limited liability on 12 November 2014
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"Controlling Shareholder(s)"	has the meaning ascribed to it under the Listing Rules
"Corporate Governance Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"Director(s)"	the director(s) of the Company
"EIS Option(s)"	the option(s) granted and to be granted to the Directors and employees of the Group under the Employee Incentive Scheme
"EIS Share(s)"	the Share(s) under the EIS Options which are directly held by Le An Xin
"Employee Incentive Scheme" or "EIS"	the scheme adopted by the Company on 26 December 2014, as amended or otherwise modified from time to time, to grant options to the incentive targets
"Glorious Peace"	Glorious Peace Limited (安鑫有限公司), a company incorporated under the laws of BVI on 10 November 2014, an indirect wholly-owned subsidiary of Ping An and our Controlling Shareholder

"Group", "the Group", "we", "us" or "our"	the Company, its subsidiaries and the Operating Entities or, where the context so requires, in respect of the period prior to the Company becoming the holding company of its present subsidiaries, such subsidiaries as if they were subsidiaries of the Company at the relevant time
"Health Insurance"/ "Ping An Health Insurance"	Ping An Health Insurance Company Ltd. (平安健康保險股份有限公司), a company incorporated under the laws of the PRC on 13 June 2005 and a subsidiary of Ping An
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong Share Registrar"	Computershare Hong Kong Investor Services Limited
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the People's Republic of China
"IFRS"	International Financial Reporting Standard
"Independent Third Party(ies)"	has the meaning ascribed to it under the Listing Rules
"Le An Xin"	Le An Xin (PTC) Limited, a company incorporated under the laws of BVI on 17 October 2017
"Life Insurance"/ "Ping An Life Insurance"	Ping An Life Insurance Company of China, Ltd. (中國平安人壽保險股份有限公司), a company incorporated under the laws of the PRC on 17 December 2002 and a subsidiary of Ping An
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange
"Listing Date"	4 May 2018, the date on which the Shares were listed and on which dealings in the Shares were first permitted to take place on the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"Lufax Holding"	Lufax Holding Ltd. (陸金所控股有限公司), a company incorporated under the laws of the Cayman Islands on 2 December 2014 whose shares are dually listed on the New York Stock Exchange (NYSE: LU) and the Hong Kong Stock Exchange (HKEX: 06623)

"Main Board"	the stock market (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
"Model Code"	Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
"Nomination and Remuneration Committee"	Nomination and Remuneration Committee under the Board
"OneConnect"	OneConnect Financial Technology Co., Ltd. (壹賬通金融科技有限公司)
"Operating Entities"	the entities we control through the contractual arrangements, namely Ping An Health Cloud and its subsidiaries
"Paying users"	users who purchase products and/or services on our platform via apps, WAP (Wireless Application Protocol) or plug-ins at least once during a period of time
"Ping An"/"Ping An Insurance (Group)"	Ping An Insurance (Group) Company of China, Ltd. (中國平安保險(集團)股份有限公司), a company incorporated under the laws of the PRC whose shares are dually listed on the Shanghai Stock Exchange and the Stock Exchange (SSE: 601318; SEHK: 2318). It is our Controlling Shareholder
"Ping An Annuity"	Ping An Annuity Insurance Company Ltd. (平安養老保險股份有限公司), a company incorporated under the laws of the PRC on 13 December 2004 and a subsidiary of Ping An
"Ping An Asset Management"	Ping An Asset Management Co., Ltd. (平安資產管理有限責任公司), a company incorporated under the laws of the PRC on 27 May 2005, a subsidiary of Ping An
"Ping An Group"	Ping An and its subsidiaries
"Ping An Health Cloud" or "PAHC"	Ping An Health Cloud Company Limited (平安健康互聯網股份有限公司), a company incorporated under the laws of the PRC on 20 August 2014 and one of our Operating Entities
"Pingan Yingjian"	Pingan Yingjian Medical Management (Shanghai) Limited (平安盈健醫療管理(上海)有限公司), a company incorporated under the laws of the PRC on 24 April 2015, a subsidiary of Ping An Health Cloud and one of our Operating Entities

Definitions

"Property & Casualty Insurance"/ "Ping An Property & Casualty Insurance"	Ping An Property & Casualty Insurance Company of China, Ltd. (中國平安財產保險股份有限公司), a company incorporated under the laws of the PRC on 24 December 2002 and a subsidiary of Ping An
"Prospectus"	the prospectus of the Company dated 23 April 2018
"Reporting Period"	the six months ended 30 June 2026
"RMB" or "Renminbi"	Renminbi, the lawful currency of China
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Share(s)"	ordinary share(s) in the share capital of the Company with a par value of USD0.00001 each before share subdivision and with a par value of USD0.000005 each after share subdivision
"Shareholder(s)"	holder(s) of the Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed to it under the Listing Rules
"substantial shareholder(s)"	has the meaning ascribed to it under the Listing Rules
"USD"	United States dollars, the lawful currency of the United States
"Yingjian Enterprise Management Consulting"	Yingjian Enterprise Management Consulting (Shanghai) Co., Ltd. (盈健企業管理諮詢(上海)有限公司), a company incorporated under the laws of the PRC on 19 December 2014 and one of the shareholders of Pingan Yingjian
"%"	per cent